India's DRL, U.K.'s GSK At Odds On Bid To Buy 5 Percent Of DRL
This article was originally published in PharmAsia News
Executive Summary
A bid to buy a chunk of Dr. Reddy's Laboratories by U.K.-based GlaxoSmithKline may fall through because the two parties could not agree on terms